Medi-Ject moves ahead with needle-free device
This article was originally published in Clinica
Medi-Ject claims to have made an important development with its potential alternative drug delivery method for the treatment of male impotence. It has completed an initial study of its needle-free injector using a dye solution to test the device for acute tissue trauma. The Minneapolis, Minnesota-based company's chairman and CEO, Dr Franklin Pass, said the study was a crucial first step in bringing to market a needle-free intrapenile delivery system for vasoactive drugs.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.